Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn

JAMA - Journal of the American Medical Association

Volumn 313, Issue 21, 2015, Pages 2142-2151

  Huybrechts, Krista F ^a,b   Bateman, Brian T ^a,b,c   Palmsten, Kristin ^c   Desai, Rishi J ^a   Patorno, Elisabetta ^a,b   Gopalakrishnan, Chandrasekar ^a   Levin, Raisa ^a   Mogun, Helen ^a   Hernandez Diaz, Sonia ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; COHORT ANALYSIS; DELIVERY; DEPRESSION; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MENSTRUAL CYCLE; MONOTHERAPY; NEWBORN; NEWBORN DISEASE; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; ADULT; PERSISTENT FETAL CIRCULATION SYNDROME; RISK FACTOR; STATISTICAL MODEL; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY TRIMESTER, THIRD; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 84930419421     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.5605     Document Type: Article

References (39)

1. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.Pediatrics. 2000;105(1 pt 1):14-20.
2. Puthiyachirakkal M, Mhanna MJ. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review. Front Pediatr. 2013;1:23.
3. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol. 2005;29(1):8-14.
4. Clark RH, Kueser TJ, Walker MW, et al Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000; 342(7):469-474.
5. Clark RH, Huckaby JL, Kueser TJ, et al Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J Perinatol. 2003;23 (4):300-303.
6. Glass P, Wagner AE, Papero PH, et al. Neurodevelopmental status at age five years of neonates treated with extracorporeal membrane oxygenation.JPediatr. 1995;127(3):447-457.
7. US Food and Drug Administration. Public health advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124348.htm. Accessed January 7, 2015.
8. Chambers CD, Hernández-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-587.
9. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17(8):801-806.
10. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84(1):23-27.
11. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18 (3):246-252.
12. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors.Am J Perinatol. 2011;28(1):19-24.
13. US Food and Drug Administration. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. http://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed January 7, 2015.
14. Palmsten K, Huybrechts KF, Mogun H, et al. Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One. 2013;8(6):e67405. doi:10.1371/journal.pone.0067405.
15. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf. 2013;22(1):16-24.
16. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am. 2009;56(3):579-600.
17. Centers for Medicare & Medicaid Services. Medicaid Analytic eXtract (MAX) general information. MAX 1999-2005 state claims anomalies from the "2005 files" zipped file within the "MAX Data 2005 to 2008 general information, data dictionaries, data element lists, data anomalies, validation table measures and SAS loads zipped file. http://www.cms.gov/research-statistics-data-and-systems/computer-data-and-systems/medicaiddatasourcesgeninfo/maxgeneralinformation.html. Accessed December 22, 2014.
18. Palmsten K, Huybrechts KF, Kowal MK, Mogun H, Hernández-Díaz S. Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiol Drug Saf. 2014;23(6):646-655.
19. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007;120(2):e272-e282.
20. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154 (9):854-864.
21. Palmsten K, Huybrechts KF, Kowal M, Hernández-Díaz S. To adjust or not to adjust for perinatal factors when assessing pregnancy exposures? Abstract presented at: 25th Annual Meeting of the Society for Pediatric and Perinatal Epidemiologic Research (SPER); June 25-27, 2012; Minneapolis, MN.
22. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20 (4):488-495.
23. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137(8): 693-695.
24. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522.
25. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397-2407.
26. Delaney C, Cornfield DN. Risk factors for persistent pulmonary hypertension of the newborn.Pulm Circ. 2012;2(1):15-20.
27. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.
28. Abman SH. New developments in the pathogenesis and treatment of neonatal pulmonary hypertension. Pediatr Pulmonol Suppl. 1999;18: 201-204.
29. Levin DL, Mills LJ, Weinberg AG. Hemodynamic, pulmonary vascular, and myocardial abnormalities secondary to pharmacologic constriction of the fetal ductus arteriosus: a possible mechanism for persistent pulmonary hypertension and transient tricuspid insufficiency in the newborn infant. Circulation. 1979;60(2):360-364.
30. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2005;39(6): 492-503.
31. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:d8012.
32. Rothman K, Greenland S, Lash T. Modern Epidemiology. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008.
33. Bjøro K, Stray-Pedersen S. In vitro perfusion studies on human umbilical arteries, I: vasoactive effects of serotonin, PGF2 alpha and PGE2. Acta Obstet Gynecol Scand. 1986;65(4):351-355.
34. Haugen G, Bjøro K, Stray-Pedersen S. Vasoactive effects of intra- and extravascular serotonin, PGE2 and PGF2 alpha in human umbilical arteries. Gynecol Obstet Invest. 1991;31(4):208-212.
35. Yaron I, Shirazi I, Judovich R, Levartovsky D, Caspi D, Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 1999;42 (12):2561-2568.
36. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361(9368):1533-1544.
37. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One. 2014;9(3):e92778.
38. Palmsten K, Hernández-Díaz S, Huybrechts KF, et al. Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ.2013; 347:f4877.
39. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295(5): 499-507.